Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials

• by Maria Esposito, Juan Manuel Morón-Ocaña, Aditya K. Gupta, Jordi Galván, Ayoub Bentohami, Frank Freischläger

• July 1, 2026

Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”

• by Saroja Rao, Isabella Midura, Kathyana P. Santiago Mangual, Leon I. Igel, Katherine H. Saunders, Jocelyn Carter, Jenny E. Murase, Arianne Shadi Kourosh

• August 11, 2026

Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry

• by Jennifer Beecker, Lorne Albrecht, Ignacio Dei-Cas, Melinda Gooderham, Charles Lynde, Kim A. Papp, Paul Keown, Antonio Vieira, Mahmoud S. Farag, Marie Maguin, Tanya Zappitelli, Philip S. Helliwell

• July 21, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

• by Kathryn Wighton

• June 11, 2026

• 2 min